Objective: The HeRO graft is a technique for vascular access in patients with limited treatment options; however, the published results with the HeRO graft are diverging. We therefore conducted a single-center study.
Methods: Patient records between July 2014 and February 2020 from Vascular Access Unit of the Department of Vascular and Endovascular Surgery of University Clinic of Cologne (Germany) were reviewed. Retrospective data was analysed from patients with a HeRo graft ( = 18).
Results: Eighteen patients were enrolled in the study. The mean age of the patients was 62.8 ± 17.24 years. During the follow-up period, no patients died from complications related to the HeRO graft. Each patient had a mean of 1.94 concomitant diseases. The primary patency rates of the HeRO graft at 3, 6, 12, 18, and 24 months were 61.1%, 50%, 16.7%, 11.1%, and 5.6%, respectively. The secondary patency rates at the same time intervals were 77.8%, 72.8%, 55.6% 55.6%, and 55.6%, respectively. There were 44 re-operations per year, or 2.4 operations per patient. The main cause of acute complications was acute graft occlusions after HERO graft implantation. An infection after the graft implantation occurred in five (27.7%) patients, leading to graft explanation in 2 cases.
Conclusion: The use of the HERO graft is a valuable alternative method for providing a durable dialysis access in patients with limited access options. The secondary patency and survival are good with a low infection rate.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/17085381241259645 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
From Hero to Zero: A Single Center Retrospective Review of the Utility of Routine Physical Crossmatching.
Am J Transplant
January 2025
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA. Electronic address:
Pre-transplantation HLA antibody testing is necessary to assess compatibility between donor and recipient pairs. Over the past decade, the virtual crossmatch (VXM) has replaced the physical crossmatch (PXM) as the main assessment of pre-transplant histocompatibility. At our center, most transplants have proceeded based solely on the VXM, followed by a retrospective PXM.
View Article and Find Full Text PDFLong-Term Outcomes and Quality of Life of High-Risk Neuroblastoma Patients Treated with a Multimodal Treatment Including Anti-GD2 Immunotherapy: A Retrospective Cohort Study.
Cancers (Basel)
January 2025
Department of Haematology and Oncology, University Children's Hospital, Eberhard Karls University Tuebingen, 72076 Tuebingen, Germany.
Background: The incorporation of anti-GD2 antibodies such as ch14.18/SP2/0 into the multimodal treatment of high-risk neuroblastoma (HR-NB) patients has improved their outcomes. As studies assessing the long-term outcomes, long-term sequelae, and health-related quality of life (HRQoL) of this treatment are limited, this retrospective analysis aimed to explore these.
View Article and Find Full Text PDFAlternatives for exhausted dialysis access.
Semin Vasc Surg
December 2024
Department of Surgery, Division of Vascular and Endovascular Surgery, Duke University Medical Center, Durham, NC. Electronic address:
Hemodialysis (HD) access failure is a frequent problem encountered by vascular surgeons. As treatment of end-stage renal disease improves and patients live longer on HD, eventual exhaustion of traditional upper extremity HD access is common. Efforts to preserve and maintain these accesses are essential.
View Article and Find Full Text PDFGut physiology and environment explain variations in human gut microbiome composition and metabolism.
Nat Microbiol
December 2024
Department of Nutrition, Exercise and Sports, University of Copenhagen, Frederiksberg, Denmark.
The human gut microbiome is highly personal. However, the contribution of gut physiology and environment to variations in the gut microbiome remains understudied. Here we performed an observational trial using multi-omics to profile microbiome composition and metabolism in 61 healthy adults for 9 consecutive days.
View Article and Find Full Text PDFCell-based therapies reverse the heart failure-altered right ventricular proteome towards a pre-disease state.
Stem Cell Res Ther
November 2024
Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, 391 Technology Way, Winston-Salem, NC, 27101, USA.
Article Synopsis
- Congenital heart defects can cause right ventricular (RV) pressure overload, leading to heart failure, prompting research into cell-based therapies like mesenchymal stromal cells (MSCs) and c-kit positive cells (CPCs) for restoring function.
- In a study, juvenile rats underwent pulmonary artery banding to induce RV pressure overload, followed by the injection of different cell types, with results analyzed using advanced protein profiling techniques.
- The findings showed that MSC therapy significantly reversed changes in RV proteins caused by pressure overload, outperforming other cell types, indicating the potential effectiveness of these therapies in cardiac recovery.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!